COMPARISON OF THYROID HORMONE LEVELS FOUND WITH NORMAL THYROID FUNCTIONING, C

甲状腺激素水平与正常甲状腺功能的比较,C

基本信息

  • 批准号:
    7608284
  • 负责人:
  • 金额:
    $ 2.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-12-01 至 2007-11-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this project is to determine what combination of thyroid hormones provides optimum replacement therapy for hypothyroidism. In an individual with a functioning thyroid gland there are two circulating thyroid hormones, thyroxine and triiodothyronine. Although some triiodothyronine is produced within the thytoid gland itself, the majority is produced in the periphery from thyroxine. Triiodothyronine also has a much shorter half-life than thyroxine. At the present time, standard thyroid hormone replacement consists of synthetic thyroxine (levothyroxine) alone. Although levothyroxine is converted into triiodothyronine in the circulation, it is not clear that the triiodothyronine levels with replacement therapy are equal to those seen with intact thyroid function. A recent study using a combination of levothyroxine and triiodothyronine indicated a patient preference for the combination therapy. Therefore, the overall hypothesis of this project is that levothyroxine replacement results in a subtle deficiency of triiodothyronine, and that levothyroxine thus provides incomplete treatment for hypothyroidism. Specific Aim 1: To compare circulating thyroxine and triiodothyronine concentrations in individuals with normal thyroid function, prior to thyroidectomy, with concentrations achieved form thyroid hormone replacement with levothyroxine, after thyroidectomy. The initial hypothesis to be tested in this project is whether, within individual patients, standard replacement with levothyroxine alone results in lower serum levels of triiodothyronine than those seen while the thyroid gland is functioning. Participants will be euthyroid individuals who are scheduled for thyroidectomy for benign nodular disease or thyroid cancer. Serum triiodothyronine levels prior to thyroid surgery will be compared with those after thyroidectomy when participants have been stabilized on levothyroxine therapy, in order to determine if levothyroxine replacement results in lower, sub-physiologic triiodothyronine levels. Specific Aim 2: To identify a panel of genes whose level of expression is altered by thyroid hormone. Adequate treatment of hypothyroidism is judged by many parameters. These include thyroid hormone and thyroid stimulating hormone levels: signs, symptoms, and biochemical indices of thyroid status; and patient mood, neuropsychologic functioning, and satisfaction. Another hypothesis of this project is that a panel of genes can be identified whose expression level is reflective of thyroid status. Complimentary DNA microarray technology will be used to develop a gene panel whose expression is regulated by thyroid hormone. Such an index of thyroid status should be particularly sensitive to changes in thyroid hormone levels, and to addition of triiodothyronine to a treatment regimen. This gene panel will be included in the biochemical markers used to assess thyroid status in specific aims three and four. Specific Aim 3: To compare several replacement regimens using different ratios of levothyroxine and triiodothyronine, to determine which has the most favorable impact on indices of thyroid status. In addition, the triiodothyronine level achieved by the regimen that best reverses the indices of hypothyroidism will be compared with the levels of triiodothyronine seen with intact thyroid function. The third hypothesis is that levothyroxine/triiodothyronine combination will provide superior treatment of hypothyroidism. Biochemical, physiologic and psychologic indices of thyroid status will be compared during combination therapy with several ratios of levothyroxine and triiodothyronine to indices during treatment with levothyroxine alone. Serum triiodothyronine levels will also be correlated with thyroid status to determine if the regimen that most closely reproduces the triiodothyronine levels seen with intact thyroid function also has the most favorable impact on the physiologic, biochemical, and psychologic indices of thyroid status. Specific Aim 4: To compare indices of thyroid hormone status during replacement with a levothyroxine/sustained release triiodothyronine combination to indices achieved with an optimal levothyroxine/triiodothyronine regimen. The final hypothesis of this project is that sustained release triiodothyronine will be superior to commercially available triiodothyronine. Because of its short half-life, replacement with triiodothyronine leads to considerable fluctuations in its circulating levels. Use of a new sustained release product, which results in steady triiodothyronine levels, will furnish more physiologic replacement. This will be tested against treatment with levothyroxine, and levothyroxine and triiodothyronine.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 该项目的目的是确定甲状腺激素的组合为甲状腺功能减退症提供最佳的替代治疗。甲状腺功能正常的个体体内有两种循环的甲状腺激素,甲状腺素和三碘甲状腺原氨酸。尽管一些三碘甲状腺原氨酸是在甲状腺本身内产生的,但大部分是在外周由甲状腺素产生的。三碘甲状腺原氨酸的半衰期也比甲状腺素短得多。目前,标准的甲状腺激素替代品仅由合成甲状腺素(左旋甲状腺素)组成。虽然左旋甲状腺素在循环中转化为三碘甲状腺原氨酸,但目前尚不清楚替代治疗后的三碘甲状腺原氨酸水平是否与甲状腺功能完好时相同。最近的一项使用左旋甲状腺素和三碘甲状腺原氨酸联合治疗的研究表明,患者偏好联合治疗。因此,该项目的总体假设是,左旋甲状腺素替代导致三碘甲状腺原氨酸的轻微缺乏,因此左旋甲状腺素对甲状腺功能减退症提供了不完全的治疗。 具体目标1:比较甲状腺功能正常的个体在甲状腺切除术前的循环甲状腺素和三碘甲状腺原氨酸浓度,以及甲状腺切除术后用左旋甲状腺素替代甲状腺激素所达到的浓度。 在这个项目中要检验的最初假设是,在个体患者中,单独用左旋甲状腺素标准替代是否会导致血清三碘甲状腺原氨酸水平低于甲状腺功能正常时的水平。受试者将是甲状腺功能正常的个体,计划因良性结节性疾病或甲状腺癌接受甲状腺切除术。甲状腺手术前的血清三碘甲状腺原氨酸水平将与甲状腺切除术后的水平进行比较,此时受试者已稳定接受左甲状腺素治疗,以确定左甲状腺素替代是否导致较低的亚生理三碘甲状腺原氨酸水平。 具体目标2:确定一组基因的表达水平被甲状腺激素改变。甲状腺功能减退症的适当治疗是由许多参数判断的。这些指标包括甲状腺激素和促甲状腺激素水平;甲状腺状态的体征、症状和生化指标;以及患者情绪、神经心理功能和满意度。该项目的另一个假设是,可以鉴定一组基因,其表达水平反映了甲状腺状态。免费DNA微阵列技术将用于开发一个基因组,其表达受甲状腺激素调节。这种甲状腺状态的指数应该对甲状腺激素水平的变化特别敏感,并且对治疗方案中添加三碘甲状腺原氨酸特别敏感。该基因组将被纳入用于评估特定目标3和4中甲状腺状态的生化标志物中。 具体目标3:比较使用不同比例的左旋甲状腺素和三碘甲状腺原氨酸的几种替代方案,以确定哪种方案对甲状腺状态指数的影响最有利。此外,将通过最佳逆转甲状腺功能减退指数的方案实现的三碘甲状腺原氨酸水平与甲状腺功能完整时观察到的三碘甲状腺原氨酸水平进行比较。 第三个假设是左旋甲状腺素/三碘甲状腺原氨酸联合治疗甲状腺功能减退症将提供上级治疗。甲状腺状态的生化、生理和心理指标将在左旋甲状腺素和三碘甲状腺原氨酸的几种比例的联合治疗期间与左旋甲状腺素单独治疗期间的指标进行比较。血清三碘甲状腺原氨酸水平也将与甲状腺状态相关,以确定最接近地再现甲状腺功能完整时所见的三碘甲状腺原氨酸水平的方案是否也对甲状腺状态的生理、生化和心理指标具有最有利的影响。 具体目标4:比较左甲状腺素/缓释三碘甲状腺原氨酸组合替代期间的甲状腺激素状态指数与最佳左甲状腺素/三碘甲状腺原氨酸方案达到的指数。 本项目的最终假设是缓释三碘甲状腺原氨酸将优于市售三碘甲状腺原氨酸。由于其半衰期短,用三碘甲状腺原氨酸替代会导致其循环水平的相当大的波动。使用一种新的缓释产品,这导致稳定的三碘甲腺原氨酸水平,将提供更多的生理替代。这将针对左旋甲状腺素、左旋甲状腺素和三碘甲状腺原氨酸治疗进行测试。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JACQUELINE JONKLAAS其他文献

JACQUELINE JONKLAAS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JACQUELINE JONKLAAS', 18)}}的其他基金

SERUM SELENIUM LEVELS AND THYROID CANCER DEVELOPMENT
血清硒水平与甲状腺癌的发展
  • 批准号:
    7952002
  • 财政年份:
    2009
  • 资助金额:
    $ 2.45万
  • 项目类别:
SERUM SELENIUM LEVELS AND THYROID CANCER DEVELOPMENT
血清硒水平与甲状腺癌的发展
  • 批准号:
    7719075
  • 财政年份:
    2008
  • 资助金额:
    $ 2.45万
  • 项目类别:
COMPARISON OF THYROID HORMONE LEVELS FOUND WITH NORMAL THYROID FUNCTIONING, C
甲状腺激素水平与正常甲状腺功能的比较,C
  • 批准号:
    7719028
  • 财政年份:
    2008
  • 资助金额:
    $ 2.45万
  • 项目类别:
IDENTIFICATION OF LEUKOCYTE GENES THAT ARE REGULATED BY THYROID HORMONE
受甲状腺激素调节的白细胞基因的鉴定
  • 批准号:
    7719030
  • 财政年份:
    2008
  • 资助金额:
    $ 2.45万
  • 项目类别:
COMPARISON OF CORTISON LEVELS DURING AN ACTH STIMULATION TEST USING TANDEM MASS
使用串联质量进行 ACTH 刺激测试期间皮质醇水平的比较
  • 批准号:
    7608300
  • 财政年份:
    2006
  • 资助金额:
    $ 2.45万
  • 项目类别:
IDENTIFICATION OF LEUKOCYTE GENES THAT ARE REGULATED BY THYROID HORMONE
受甲状腺激素调节的白细胞基因的鉴定
  • 批准号:
    7608289
  • 财政年份:
    2006
  • 资助金额:
    $ 2.45万
  • 项目类别:
LEVOTHYROXINE: TRIIODOTHYRONINE COMBINATION THERAPY FOR HYPOTHYROIDISM
左旋甲状腺素:三碘甲状腺原氨酸联合治疗甲状腺功能减退症
  • 批准号:
    7199712
  • 财政年份:
    2005
  • 资助金额:
    $ 2.45万
  • 项目类别:
IDENTIFICATION OF LEUKOCYTE GENES THAT ARE REGULATED BY THYROID HORMONE
受甲状腺激素调节的白细胞基因的鉴定
  • 批准号:
    7376126
  • 财政年份:
    2005
  • 资助金额:
    $ 2.45万
  • 项目类别:
LEVOTHYROXINE: TRIIODOTHYRONINE COMBINATION THERAPY FOR HYPOTHYROIDISM
左旋甲状腺素:三碘甲状腺原氨酸联合治疗甲状腺功能减退症
  • 批准号:
    7199713
  • 财政年份:
    2005
  • 资助金额:
    $ 2.45万
  • 项目类别:
LEVOTHYROXINE: TRIIODOTHYRONINE COMBINATION THERAPY FOR HYPOTHYROIDISM
左旋甲状腺素:三碘甲状腺原氨酸联合治疗甲状腺功能减退症
  • 批准号:
    7199714
  • 财政年份:
    2005
  • 资助金额:
    $ 2.45万
  • 项目类别:

相似海外基金

Resting Concentrations of Bone Biochemical Markers in Adolescent Female Athletes of High-impact and
高冲击力和高强度青少年女运动员骨生化标志物的静息浓度
  • 批准号:
    564842-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 2.45万
  • 项目类别:
    University Undergraduate Student Research Awards
The utility of ultrasound and biochemical markers for the purpose of predicting cardiac failure in recipient's fetuses in twin-twin transfusion syndrome.
超声和生化标记物在预测双胎输血综合征受者胎儿心力衰竭中的应用。
  • 批准号:
    17K16875
  • 财政年份:
    2017
  • 资助金额:
    $ 2.45万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
MICA: Phase II study of the impact of AZD4017 a selective 11beta-HSD1 inhibitor on biochemical markers of bone turnover in post-menopausal osteopaenia
MICA:选择性 11β-HSD1 抑制剂 AZD4017 对绝经后骨质疏松症骨转换生化标志物影响的 II 期研究
  • 批准号:
    MR/K015176/2
  • 财政年份:
    2015
  • 资助金额:
    $ 2.45万
  • 项目类别:
    Research Grant
Development of biochemical markers for quality and/or quantity of child sleep
开发儿童睡眠质量和/或数量的生化标记物
  • 批准号:
    15K12721
  • 财政年份:
    2015
  • 资助金额:
    $ 2.45万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
MICA: Phase II study of the impact of AZD4017 a selective 11beta-HSD1 inhibitor on biochemical markers of bone turnover in post-menopausal osteopaenia
MICA:选择性 11β-HSD1 抑制剂 AZD4017 对绝经后骨质疏松症骨转换生化标志物影响的 II 期研究
  • 批准号:
    MR/K015176/1
  • 财政年份:
    2014
  • 资助金额:
    $ 2.45万
  • 项目类别:
    Research Grant
Development of assessment methodology on behaviors of water quality threatening algae in lakes considering their life cycle and using biochemical markers
考虑其生命周期并使用生化标记物开发威胁湖泊水质的藻类行为的评估方法
  • 批准号:
    25289151
  • 财政年份:
    2013
  • 资助金额:
    $ 2.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Biochemical Markers of Bone Metabolism and Paget s Disease of Bone
骨代谢和佩吉特骨病的生化标志物
  • 批准号:
    G0801462/2
  • 财政年份:
    2012
  • 资助金额:
    $ 2.45万
  • 项目类别:
    Research Grant
Evaluation for bone quality in jaw bone using biochemical markers of bone turnover
使用骨转换的生化标记物评估颌骨的骨质量
  • 批准号:
    23792296
  • 财政年份:
    2011
  • 资助金额:
    $ 2.45万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Chronic oral graft-versus-host disease: clinical risk factors, biochemical markers of disease activity and novel therapeutics
慢性口腔移植物抗宿主病:临床危险因素、疾病活动的生化标志物和新疗法
  • 批准号:
    nhmrc : 1017351
  • 财政年份:
    2011
  • 资助金额:
    $ 2.45万
  • 项目类别:
    Postgraduate Scholarships
Evaluation of pain experience in domestic fowl: associations between clinical symptoms biochemical markers and bird self-selection of analgesics
家禽疼痛体验的评估:临床症状生化标志物与家禽自我选择镇痛药之间的关联
  • 批准号:
    BB/G002738/1
  • 财政年份:
    2011
  • 资助金额:
    $ 2.45万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了